Stem cell transplantation underutilized for acute myeloid leukemia
Click Here to Manage Email Alerts
NEW ORLEANS — Utilization of hematopoietic stem cell transplantation for acute myeloid leukemia has increased over time but remains far below optimal levels, according to study results presented at ASH Annual Meeting and Exposition.
Molly Tokaz, MD, senior fellow at Fred Hutchinson Cancer Center, and colleagues reported “stark” disparities globally, with lower-than-anticipated utilization in both low-resource countries and more resource-abundant regions like North America and Europe.
Tokaz spoke with Healio about the study findings and their potential implications, as well as the importance of expanding use of this curative treatment for AML.
Collapse
Tokaz M, et al. Abstract 3638. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Click Here to Manage Email Alerts